Two or four hour [18F]FMISO-PET in HNSCC: When is the contrast best?

NuklearMedizin

Volumn 50, Issue 1, 2011, Pages 22-27

  Abolmaali, Nasreddin ^a   Haase, R ^a   Koch, A ^a   Zips, D ^a   Steinbach, J ^a   Baumann, M ^a   Kotzerke, J ^a   Zophel K ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bio imaging; Contrast to noise ratio; FMISO PET; Head and neck cancer; Radiotherapy treatment planning; Tumour to muscle ratio

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; GLUCOROS; IOPROMIDE; ULTRAVIST370; UNCLASSIFIED DRUG; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; NECK MUSCLE; POSITRON EMISSION TOMOGRAPHY; SIGNAL NOISE RATIO; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; EVALUATION; HEAD AND NECK TUMOR; IMAGE ENHANCEMENT; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA; TIME;

CARCINOMA, SMALL CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 79952078653     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-00328-10-07     Document Type: Article

References (33)

1. Brizel DM, Sibley GS, Prosnitz LR et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289. (Pubitemid 27318643)
2. Busk M, Horsman MR, Jakobsen S et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol 2009; 92: 429-436.
3. Daisne JF, Duprez T, Weynand B et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 233: 93-100.
4. 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009; 50: 1020-1027.
5. 18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009; 36: 209-218.
6. Eschmann SM, Paulsen F, Bedeshem C et al. Hypoxia-imaging with 18F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007; 83: 406-410. (Pubitemid 46915551)
7. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-260.
8. Grunbaum Z, Freauff SJ, Krohn KA et al. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 1987; 28: 68-75. (Pubitemid 17008812)
9. Hentschel M, Appold S, Schreiber A et al. Serial FDG-PET on patients with head and neck cancer: implications for radiation therapy. Int J Radiat Biol 2009; 85: 796-804.
10. Hicks RJ, Rischin D, Fisher R et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32: 1384-1391. (Pubitemid 41746841)
11. Hockel M, Knoop C, Schlenger K et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26: 45-50. (Pubitemid 23063609)
12. Hofheinz F , Dittrich S, Pötzsch C et al. Effects of cold sphere walls in PET phantom measurements on the volume reproducing threshold. Phys Med Biol 2010; 55: 1099-1113.
13. Hofheinz F, Poetzsch C, van den Hoff J. Quantitative 3D ROI volume delineation in PET: algorithm and validation. J Nucl Med 2007; 48: 1709.
14. Kotzerke J, Oehme L, Lindner O, Hellwig D. Positron emission tomography 2008 in Germany. Nuklear medizin 2010; 49: 58-64.
15. Lee NY, Mechalakos JG, Nehmeh S et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008; 70: 2-13. (Pubitemid 350251039)
16. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008; 70: 1219-1228.
17. 18F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 2008; 47: 80-85.
18. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 70: 235-242.
19. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-280.
20. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007; 17: 861-872. (Pubitemid 46772763)
21. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005; 43: 169-187. (Pubitemid 40326567)
22. 18F]FDG PET imaging in soft tissue sarcomas. Eur J Nucl Med Mol Imaging 2003; 30: 695-704.
23. 18F]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1996; 36: 417-428.
24. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine. J Clin Oncol 2006; 24: 2098-2104.
25. 18F]FMISO hypoxic volume on local control after single dose irradiation in FaDu HNSCC in nude mice. Radiother Oncol 2009; 90: 55.
26. 18F]fluoromisonidazole. Nucl Med Biol 2005; 32: 553-558.
27. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005; 5: 152.
28. 18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008; 35: 1803-1811.
29. 18F-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med 2010; 51: 37-45.
30. 18F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006; 33: 311-318.
31. Yaromina A, Thames HD, Zhou X et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010; 96: 116-122.
32. Yaromina A, Zips D, Thames HD et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice. Radiother Oncol 2006; 81: 122-129. (Pubitemid 44780780)
33. 2- polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1426-1431.